Top Markets
#1 Islamic Coin Islamic Coin +151.53%
#2 Palladium Network Palladium Network +18.73%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#4 clBTC clBTC +12.16%
#5 OpenEden OpenEden +10.74%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.75%
#7 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.73%
#8 MarsCoin MarsCoin +8.66%
#9 Mantle Staked Ether Mantle Staked Ether +8.33%
#10 Mantle Restaked ETH Mantle Restaked ETH +8.01%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

INFI
Rank in Stocks #40134
Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge,... Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.
Share Price
$0.0039
Last synced: 2023-10-27
Market Cap
$235.97K
Change (1 day)
-13.33%
Change (1 year)
0.00%
Country
US
Trade Infinity Pharmaceuticals, Inc. (INFI)

Category

Healthcare
Revenue for Infinity Pharmaceuticals, Inc. (INFI)
Revenue in Aug 2026 TTM: 0
According to Infinity Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Infinity Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE